Cargando…

Chemical Genetics Reveals an RGS/G-Protein Role in the Action of a Compound

We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and the resulting phenotypes were used as readouts in a genetic screen t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Kevin, Tertyshnikova, Svetlana, Moore, Lisa, Bjerke, Lynn, Burley, Ben, Cao, Jian, Carroll, Pamela, Choy, Robert, Doberstein, Steve, Dubaquie, Yves, Franke, Yvonne, Kopczynski, Jenny, Korswagen, Hendrik, Krystek, Stanley R, Lodge, Nicholas J, Plasterk, Ronald, Starrett, John, Stouch, Terry, Thalody, George, Wayne, Honey, van der Linden, Alexander, Zhang, Yongmei, Walker, Stephen G, Cockett, Mark, Wardwell-Swanson, Judi, Ross-Macdonald, Petra, Kindt, Rachel M
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440875/
https://www.ncbi.nlm.nih.gov/pubmed/16683034
http://dx.doi.org/10.1371/journal.pgen.0020057
Descripción
Sumario:We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and the resulting phenotypes were used as readouts in a genetic screen to identify possible molecular targets. The mutations giving resistance to compound were found to affect members of the RGS protein/G-protein complex. Studies in mammalian systems confirmed that the small molecules inhibit muscarinic G-protein coupled receptor (GPCR) signaling involving G-αq (G-protein alpha subunit). Our studies suggest that the small molecules act at the level of the RGS/G-αq signaling complex, and define new mutations in both RGS and G-αq, including a unique hypo-adapation allele of G-αq. These findings suggest that therapeutics targeted to downstream components of GPCR signaling may be effective for treatment of diseases involving inappropriate receptor activation.